Homepage
Author:
Imviva Biotech
Posted Date:
March 2, 2026
Imviva Biotech Announces Acceptance of Late-Breaking Abstract Highlighting Data from Ongoing Phase 1/2 Study of CTA313 at 15th European Lupus Meeting
Imviva Biotech
March 2, 2026
Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma
Imviva Biotech
January 28, 2026
